Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

NCT06511648 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Muscle-invasive Bladder Cancer

Interventions

DRUG: Erdafitinib monotherapy
DRUG: Cetrelimab and Erdafitinib combination

Sponsor

Spanish Oncology Genito-Urinary Group

Collaborators

[object Object]
[object Object]